Physician profile
William Eanes Courson
NPI 1720427388
$7,958.81
in general payments reported to CMS, 2019-2025
46 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $372 · 2021: $998 · 2022: $1,138 · 2023: $1,822 · 2024: $1,973 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,328.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,022.15 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $849.79 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $771.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $556.30 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $547.15 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $512.04 | 2023-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $484.37 | 2020-2025 | Jardiance, Synjardy, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $310.51 | 2022-2025 | |
| Astellas Pharma US INC | $265.85 | 2019-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $250.98 | 2021-2025 | Rexulti |
| Glaxosmithkline, LLC. | $234.80 | 2022-2025 | Shingrix, Arexvy |
| Amgen INC. | $191.24 | 2020-2025 | Repatha, Otezla, Otezla |
| Idorsia Pharmaceuticals US INC | $188.57 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $173.35 | 2023-2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $161.26 | 2021-2024 | Seglentis, Livalo, Zoryve |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Courson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.